



Dear <<Insert Name>>

<<Site and/or PI name>> is currently recruiting subjects to participate in an Otonomy Phase 3 clinical trial for Meniere's disease, which will investigate the efficacy and safety of the drug OTO-104 in subjects with Meniere's disease, as measured by the number of definitive vertigo days at the end of trial participation (Week 12).

OTO-104 is a suspension of dexamethasone in a buffered solution containing a glycol polymer, poloxamer 407. Otonomy has formulated dexamethasone, a synthetic member of the glucocorticoid class of steroid hormones in poloxamer 407, for the purpose of studying the potential benefits for intratympanic injections of OTO-104 in subjects with Meniere's disease.

We would appreciate your help identifying potential trial participants.

Each subject will be randomized 1:1 to receive a single intratympanic injection of OTO-104 or placebo. Participants will be expected to record daily vertigo experiences in a trial diary and attend 5 visits at the trial clinic.

Key eligibility criteria* includes:

- Male or female aged 18 to 75 years (inclusive)
- Diagnosis of definite unilateral Meniere's disease
- Self-reported active, definitive vertigo episodes for 2 months prior to the screening
- Documented asymmetric sensorineural hearing loss within the past 12 months
- No infection in the ear, sinuses, or upper respiratory system
- No history of intratympanic gentamicin or steroids in the affected ear
- No history of middle or inner ear surgery in the affected ear
- No history of vestibular migraine
- No history of drop attacks

*Other criteria will apply.

If you know of any patients who you think meet these key eligibility criteria and may be interested in participating, please contact me or my trial team coordinator. I am happy to discuss the trial in more detail with you and the patient and can provide you with the results of assessments and physical exams throughout the trial. Thank you for taking the time to review this information.

Sincerely,

<<Insert Dr. Name>>

[Otonomy | Phase 3 Clinical Trial for Meniere's disease](#)

<<Insert Contact Information for PI and study coordinator>>